Systematic review / meta-analysis / 2024
Taurine supplementation significantly reduced blood pressure, fasting glucose, and triglycerides in a meta-analysis of randomized controlled trials.
A meta-analysis evaluated 25 randomized controlled trials with 1,024 participants receiving 0.5 to 6 g/day of taurine for 5 to 365 days. Taurine supplementation led to statistically significant reductions in SBP (WMD = -3.999 mmHg, p = 0.017), DBP (WMD = -1.509 mmHg, p = 0.002), fasting blood glucose (WMD = -5.882 mg/dL, p = 0.018), and triglycerides (WMD = -18.315 mg/dL, p < 0.001), but not HDL-C (p = 0.155). Meta-regression revealed dose-dependent reductions in DBP (-0.0108 mmHg per g, p = 0.0297) and FBG (-0.0445 mg/dL per g, p = 0.0273). No significant adverse effects were observed compared to control groups.
- Study type
- Systematic review and meta-analysis of RCTs
- Who was studied
- 1,024 participants across 25 randomized controlled trials
- What was measured
- Metabolic syndrome parameters including SBP, DBP, fasting blood glucose, triglycerides, and HDL-C
THE PAPER
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.
Tzang CC, Chi LY, Lin LH, Lin TY, Chang KV, Wu WT, Özçakar L. Nutr Diabetes, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.